Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002198
- Locations
- 🇺🇸
PPD Development, Inc, Wilmington, North Carolina, United States
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 30
- Registration Number
- NCT00002233
- Locations
- 🇺🇸
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States
🇺🇸Miriam Hosp / Family Healthcare Ctr at SSTAR, Providence, Rhode Island, United States
Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00008554
- Locations
- 🇺🇸
Ocean View Internal Medicine, Long Beach, California, United States
🇺🇸Saint Michael's Med Ctr, Newark, New Jersey, United States
🇺🇸Hillsborough County Health Dept, Tampa, Florida, United States
A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 40
- Registration Number
- NCT00002364
- Locations
- 🇺🇸
North Broward Hosp District, Fort Lauderdale, Florida, United States
🇺🇸Kraus Med Partners, Los Angeles, California, United States
🇺🇸Marin County Specialty Clinic, Greenbrae, California, United States
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT00002239
- Locations
- 🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States
A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00002362
- Locations
- 🇺🇸
Northstar Med Clinic, Chicago, Illinois, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00002389
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Kraus Med Partners, Los Angeles, California, United States
🇺🇸Univ of Miami Dept of Medicine, Miami, Florida, United States
A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002216
- Locations
- 🇺🇸
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 40
- Registration Number
- NCT00004585
- Locations
- 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Tower Infectious Diseases / Med Associates Inc, Los Angeles, California, United States
🇺🇸North Shore Univ Hosp, Manhasset, New York, United States
A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 60
- Registration Number
- NCT00000864
- Locations
- 🇺🇸
Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
🇺🇸Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States
🇵🇷San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.